ALBIREO PHARMA, INC. (NASDAQ:ALBO) Files An 8-K Other Events
Item 8.01Other Events.
On May 18, 2017, Albireo Pharma, Inc. issued a press release
announcing plans for a Phase 3 clinical program of its lead
product candidate, A4250, in patients with progressive familial
intrahepatic cholestasis. The full text of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press release dated May 18, 2017 |
ALBIREO PHARMA, INC. (NASDAQ:ALBO) Recent Trading Information
ALBIREO PHARMA, INC. (NASDAQ:ALBO) closed its last trading session up +0.09 at 20.99 with 18,220 shares trading hands.
